Aggressive, trimodal therapy active in treatment of selected men with M1 prostate cancer

A new report in the journal Urology has shown that a subset of men with metastatic disease can be placed in long-term remission through the use of a combination of androgen deprivation therapy (ADT) + surgery + radiation therapy. … READ MORE …

“Right to try” legislation and the management of prostate cancer

As many of our readers may be aware, the “right to try” treatments using investigational new drugs outside of the clinical trials processes required by drug developers and overseen by the US Food and Drug Administration is a current “hot topic” on Capitol Hill. … READ MORE …

Revised ASCO/CCO brachytherapy guidelines

The publication of the ASCENDE-RT clinical trial (discussed here) has led to a revision in the brachytherapy guidelines (available here) issued jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO). The guidelines are for patients who choose radical therapy rather than active surveillance. … READ MORE …

US-based, Phase II trial of lutetium-177 PSMA-directed endoradiotherapy

We have been provided (by the developers) with additional information about a US-based, Phase II, clinical trial of a form of radiation therapy using the targeted agent lutetium-177 prostate-specific membrane antigen 617 (177Lu-PSMA-617) for treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Finding common ground on how “best” to treat localized prostate cancer, and what to tell the patients

One of the hardest issues for newly diagnosed prostate cancer patients to deal with has long been the differences in opinion between physicians about appropriate first-line treatment (and the relevant information they are offered) — most especially for patients with localized disease. … READ MORE …

Current trends in the management of oligometastatic prostate cancer

In what one of the authors has described as “a somewhat critical and light-hearted look at our current enthusiasm for aggressive approaches to oligometastatic prostate cancer”, an article currently in press asks some serious questions about the use of metastasis-directed therapy or MTD in the management of such patients. … READ MORE …

What’s good for the patient is not always what they want

The following article was originally published in the ASCO Connection magazine on February 22, 2017 (click here for the original). It was written by Anne Katz, RN, PhD, FAAN, … READ MORE …